Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
Date:11/14/2013

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18th Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21st through 24th in San Francisco.  Glioblastoma is the most common and aggressive form of brain cancer, and new therapies are greatly needed.

DelMar will present the poster entitled, "Phase I/II study of VAL-083 in patients with recurrent malignant glioma or progressive-secondary brain tumor," from 7 pm to 9 pm on Friday, November 22nd. The abstract, number MR-028, is now published in the Journal of Neuro-Oncology and can also be found by clicking here.

About VAL-083
VAL-083 represents a first-in-class, small-molecule chemotherapeutic with a unique mechanism of action. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute (NCI), VAL-083 has shown safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.  As a potential treatment for glioblastoma, VAL-083's mechanism of action is unaffected by the expression of MGMT
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... VEGAS , March 27, 2015 Zimmer Holdings, ... efficient external fixation system for trauma patients. ... XtraFix ® External Fixation System from Zimmer ... technology and materials.   The XtraFix System ... clamps from the external fixation process, resulting in saved time, ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... China International Exhibition of Senior Care, Rehabilitation Medicine and ... senior service industry, will be held at Shanghai ... On 25 February, 2015,  Implementation Suggestions on Encouraging ... Service Industry, which was jointly issued by the Ministry ...
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
Breaking Medicine Technology:Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Final ... new transition from Pixel Film Studios, entitled TranSports. ... made exclusively for Final Cut Pro X,” said Christiana ... users the tools needed to effortlessly transition using this ... TranSports, a new and uniquely styled transition pack for ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Pitching speed, ... a history of shoulder and elbow injuries, according to new ... Medicine’s ( AOSSM ) Specialty Day. , “Our findings indicate ... a 20% increase in likelihood of a history of injury, ... with a 12% increase likelihood of a history of injury, ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
... the Albert Einstein College of Medicine in Yeshiva University ... to use radioactivity as an energy source for ... to Dr. Arturo Casadevall, chair of microbiology and immunology ... finding could trigger a recalculation of the Earth's energy ...
... currently gripping humanity, Cuban President Fidel Castro called for governments ... arms. ,The non-profit exercise of medicine is ... recent article broadcast Tuesday by the island's mass media. ... "wonderful submarine" in Great Britain, which can shoot down lethal ...
... Australian High Commissioner to India, John McCarthy, has announced ... Meghalaya, Manipur and Mizoram. ,The ... be implemented by the UN Office on Drugs and ... High Commission release said. ,The Australian ...
... A new study has found that combination asthma ... quality of life (HRQL) and greater patient-reported satisfaction ... or formoterol or placebo). ,SYMBICORT is ... long-term maintenance treatment of asthma in patients 12 ...
... new imaging technique - magnetic resonance elastography (MRE) - is ... ,The studies were conducted by a team ... ,As part of one study, researchers conducted MRE examinations ... volunteers. ,The researchers found that MRE accurately ...
... have to leave physical bumps and bruises to ... environment. Behavior that intentionally harms another individual, ... aggression), is just as significant a concern for ... Dr. Sara Goldstein from Montclair State University and ...
Cached Medicine News:Health News:Astronauts can Now Feed on 'radiation-eating' Fungi 2Health News:Australia Contributes Additional Funds for HIV Prevention in North-East 2Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:Psychological Bullying Hits Just as Hard 2
... hand-held, point-of-care device for the qualitative detection of ... The TOX/See device can detect up to nine ... to 8 minutes and requires only a few ... packaged to maximize convenience and ease of use. ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... Solution offers relief from CTS pain and ... from other over-the-counter CTS treatments. It is ... sleep, the Carpal Solution gently reshapes soft ... and eliminates hand pain, numbness and sleep ...
... is a manual Modified Westergren system ... rate (ESR) of whole blood in ... Tubes. The rack will accommodate up ... Manual Rack exhibits >96% correlation to ...
Medicine Products: